Stay updated on CC-122/Nivolumab Combo in Unresectable HCC Clinical Trial
Sign up to get notified when there's something new on the CC-122/Nivolumab Combo in Unresectable HCC Clinical Trial page.

Latest updates to the CC-122/Nivolumab Combo in Unresectable HCC Clinical Trial page
- Check5 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3 on the page. This update does not affect study details or user-facing functionality.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedRevision label updated from v3.4.1 to v3.4.2. The page content remains unchanged.SummaryDifference0.0%

- Check40 days agoChange DetectedThe page shows a revision update from v3.4.0 to v3.4.1, which is a minor software revision with no content changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check48 days agoChange DetectedThe page shows minor UI/label updates: a glossary toggle was added, QC-related labels were standardized, FEAR Act labeling updated, and the revision footer now shows Revision: v3.4.0 (replacing v3.3.4).SummaryDifference0.2%

- Check62 days agoChange DetectedRevision label updated from v3.3.3 to v3.3.4; no visible changes to content or layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check84 days agoChange DetectedLocations section now shows a general Locations entry with California, Florida, New York, and Texas removed as separate blocks; revision updated to v3.3.3.SummaryDifference0.5%

Stay in the know with updates to CC-122/Nivolumab Combo in Unresectable HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CC-122/Nivolumab Combo in Unresectable HCC Clinical Trial page.